Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNASTY-Breast02: DB-1303 vs investigator’s choice chemotherapy in HER2-low, HR-positive metastatic breast cancer
CTR20233708Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab pamirtecan in breast cancer, sponsored by AbbVie Inc.. Started Jan 2024; status: active.
02
Drugs
trastuzumab pamirtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233708.